Interaction of β-Funaltrexamine with [3H]CycloFOXY binding in rat brain

Further evidence that β-FNA alkylates the opioid receptor complex

R. B. Rothman, V. Bykov, A. Mahboubi, J. B. Long, Q. Jiang, Frank Porreca, B. R. De Costa, A. E. Jacobson, K. C. Rice, J. W. Holaday

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

β-Funaltrexamine (β-FNA) is an alkylating derivative of naltrexone. In addition to acting as an irreversible inhibitor of μ-receptor-mediated physiological effects, intracerebroventricular (i.c.v.) administration of β-FNA to rat attenuates the ability of selective δ receptor antagonists and naloxone to reverse δ receptor-mediated effects. Moreover, recent work demonstrated that i.c.v. administration of β-FNA alters the conformation of the opioid receptor complex, as inferred by a decrease in the Bmax of the lower affinity [3H][D-ala2,D-leu5]enkephalin binding site. Consistent with the decreased potency of naloxone as an inhibitor of δ receptor mediated effects, β-FNA doubled the naloxone IC50 for displacing [3H][D-ala2,D-leu5]enkephalin from its lower affinity binding site. These data collectively support the hypothesis that the opioid receptor complex postulated to mediate μ-δ interactions in vivo is identical to the opioid receptor complex as defined by vitro ligand binding studies. A direct prediction of this hypothesis is that β-FNA should increase the Kd of antagonists for the μ binding site (μ(cx)) of the receptor complex. The data reported in this paper demonstrate that β-FNA doubled the IC50 of the potent narcotic antagonist, 6-desoxy-6β-fluoronaltrexone (cycloFOXY) for displacing [3H][D-ala2,D-leu5]enkephalin from its lower affinity binding site, and doubled the Kd of [3H]cycloFOXY for its μ binding site, providing additional data that the μ binding site labeled by [3H]cycloFOXY is the μ binding site of the opioid receptor complex. β-FNA also altered the κ binding site labeled by [3H]cycloFOXY, and when administered intrathecally to mice, β-FNA produced a longlasting antinociception in the acetic acid writhing test.

Original languageEnglish (US)
Pages (from-to)86-99
Number of pages14
JournalSynapse
Volume8
Issue number2
StatePublished - 1991

Fingerprint

Opioid Receptors
Binding Sites
Brain
Naloxone
Inhibitory Concentration 50
Naltrexone
Narcotic Antagonists
Acetic Acid
6-deoxy-6-fluoronaltrexone
Ligands
Ala(2)-enkephalinamide-met

ASJC Scopus subject areas

  • Physiology
  • Neuroscience(all)
  • Pharmacology

Cite this

Rothman, R. B., Bykov, V., Mahboubi, A., Long, J. B., Jiang, Q., Porreca, F., ... Holaday, J. W. (1991). Interaction of β-Funaltrexamine with [3H]CycloFOXY binding in rat brain: Further evidence that β-FNA alkylates the opioid receptor complex. Synapse, 8(2), 86-99.

Interaction of β-Funaltrexamine with [3H]CycloFOXY binding in rat brain : Further evidence that β-FNA alkylates the opioid receptor complex. / Rothman, R. B.; Bykov, V.; Mahboubi, A.; Long, J. B.; Jiang, Q.; Porreca, Frank; De Costa, B. R.; Jacobson, A. E.; Rice, K. C.; Holaday, J. W.

In: Synapse, Vol. 8, No. 2, 1991, p. 86-99.

Research output: Contribution to journalArticle

Rothman, RB, Bykov, V, Mahboubi, A, Long, JB, Jiang, Q, Porreca, F, De Costa, BR, Jacobson, AE, Rice, KC & Holaday, JW 1991, 'Interaction of β-Funaltrexamine with [3H]CycloFOXY binding in rat brain: Further evidence that β-FNA alkylates the opioid receptor complex', Synapse, vol. 8, no. 2, pp. 86-99.
Rothman, R. B. ; Bykov, V. ; Mahboubi, A. ; Long, J. B. ; Jiang, Q. ; Porreca, Frank ; De Costa, B. R. ; Jacobson, A. E. ; Rice, K. C. ; Holaday, J. W. / Interaction of β-Funaltrexamine with [3H]CycloFOXY binding in rat brain : Further evidence that β-FNA alkylates the opioid receptor complex. In: Synapse. 1991 ; Vol. 8, No. 2. pp. 86-99.
@article{479d46eae6c349dba5c83efbefd667ea,
title = "Interaction of β-Funaltrexamine with [3H]CycloFOXY binding in rat brain: Further evidence that β-FNA alkylates the opioid receptor complex",
abstract = "β-Funaltrexamine (β-FNA) is an alkylating derivative of naltrexone. In addition to acting as an irreversible inhibitor of μ-receptor-mediated physiological effects, intracerebroventricular (i.c.v.) administration of β-FNA to rat attenuates the ability of selective δ receptor antagonists and naloxone to reverse δ receptor-mediated effects. Moreover, recent work demonstrated that i.c.v. administration of β-FNA alters the conformation of the opioid receptor complex, as inferred by a decrease in the Bmax of the lower affinity [3H][D-ala2,D-leu5]enkephalin binding site. Consistent with the decreased potency of naloxone as an inhibitor of δ receptor mediated effects, β-FNA doubled the naloxone IC50 for displacing [3H][D-ala2,D-leu5]enkephalin from its lower affinity binding site. These data collectively support the hypothesis that the opioid receptor complex postulated to mediate μ-δ interactions in vivo is identical to the opioid receptor complex as defined by vitro ligand binding studies. A direct prediction of this hypothesis is that β-FNA should increase the Kd of antagonists for the μ binding site (μ(cx)) of the receptor complex. The data reported in this paper demonstrate that β-FNA doubled the IC50 of the potent narcotic antagonist, 6-desoxy-6β-fluoronaltrexone (cycloFOXY) for displacing [3H][D-ala2,D-leu5]enkephalin from its lower affinity binding site, and doubled the Kd of [3H]cycloFOXY for its μ binding site, providing additional data that the μ binding site labeled by [3H]cycloFOXY is the μ binding site of the opioid receptor complex. β-FNA also altered the κ binding site labeled by [3H]cycloFOXY, and when administered intrathecally to mice, β-FNA produced a longlasting antinociception in the acetic acid writhing test.",
author = "Rothman, {R. B.} and V. Bykov and A. Mahboubi and Long, {J. B.} and Q. Jiang and Frank Porreca and {De Costa}, {B. R.} and Jacobson, {A. E.} and Rice, {K. C.} and Holaday, {J. W.}",
year = "1991",
language = "English (US)",
volume = "8",
pages = "86--99",
journal = "Synapse",
issn = "0887-4476",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Interaction of β-Funaltrexamine with [3H]CycloFOXY binding in rat brain

T2 - Further evidence that β-FNA alkylates the opioid receptor complex

AU - Rothman, R. B.

AU - Bykov, V.

AU - Mahboubi, A.

AU - Long, J. B.

AU - Jiang, Q.

AU - Porreca, Frank

AU - De Costa, B. R.

AU - Jacobson, A. E.

AU - Rice, K. C.

AU - Holaday, J. W.

PY - 1991

Y1 - 1991

N2 - β-Funaltrexamine (β-FNA) is an alkylating derivative of naltrexone. In addition to acting as an irreversible inhibitor of μ-receptor-mediated physiological effects, intracerebroventricular (i.c.v.) administration of β-FNA to rat attenuates the ability of selective δ receptor antagonists and naloxone to reverse δ receptor-mediated effects. Moreover, recent work demonstrated that i.c.v. administration of β-FNA alters the conformation of the opioid receptor complex, as inferred by a decrease in the Bmax of the lower affinity [3H][D-ala2,D-leu5]enkephalin binding site. Consistent with the decreased potency of naloxone as an inhibitor of δ receptor mediated effects, β-FNA doubled the naloxone IC50 for displacing [3H][D-ala2,D-leu5]enkephalin from its lower affinity binding site. These data collectively support the hypothesis that the opioid receptor complex postulated to mediate μ-δ interactions in vivo is identical to the opioid receptor complex as defined by vitro ligand binding studies. A direct prediction of this hypothesis is that β-FNA should increase the Kd of antagonists for the μ binding site (μ(cx)) of the receptor complex. The data reported in this paper demonstrate that β-FNA doubled the IC50 of the potent narcotic antagonist, 6-desoxy-6β-fluoronaltrexone (cycloFOXY) for displacing [3H][D-ala2,D-leu5]enkephalin from its lower affinity binding site, and doubled the Kd of [3H]cycloFOXY for its μ binding site, providing additional data that the μ binding site labeled by [3H]cycloFOXY is the μ binding site of the opioid receptor complex. β-FNA also altered the κ binding site labeled by [3H]cycloFOXY, and when administered intrathecally to mice, β-FNA produced a longlasting antinociception in the acetic acid writhing test.

AB - β-Funaltrexamine (β-FNA) is an alkylating derivative of naltrexone. In addition to acting as an irreversible inhibitor of μ-receptor-mediated physiological effects, intracerebroventricular (i.c.v.) administration of β-FNA to rat attenuates the ability of selective δ receptor antagonists and naloxone to reverse δ receptor-mediated effects. Moreover, recent work demonstrated that i.c.v. administration of β-FNA alters the conformation of the opioid receptor complex, as inferred by a decrease in the Bmax of the lower affinity [3H][D-ala2,D-leu5]enkephalin binding site. Consistent with the decreased potency of naloxone as an inhibitor of δ receptor mediated effects, β-FNA doubled the naloxone IC50 for displacing [3H][D-ala2,D-leu5]enkephalin from its lower affinity binding site. These data collectively support the hypothesis that the opioid receptor complex postulated to mediate μ-δ interactions in vivo is identical to the opioid receptor complex as defined by vitro ligand binding studies. A direct prediction of this hypothesis is that β-FNA should increase the Kd of antagonists for the μ binding site (μ(cx)) of the receptor complex. The data reported in this paper demonstrate that β-FNA doubled the IC50 of the potent narcotic antagonist, 6-desoxy-6β-fluoronaltrexone (cycloFOXY) for displacing [3H][D-ala2,D-leu5]enkephalin from its lower affinity binding site, and doubled the Kd of [3H]cycloFOXY for its μ binding site, providing additional data that the μ binding site labeled by [3H]cycloFOXY is the μ binding site of the opioid receptor complex. β-FNA also altered the κ binding site labeled by [3H]cycloFOXY, and when administered intrathecally to mice, β-FNA produced a longlasting antinociception in the acetic acid writhing test.

UR - http://www.scopus.com/inward/record.url?scp=0025760174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025760174&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 86

EP - 99

JO - Synapse

JF - Synapse

SN - 0887-4476

IS - 2

ER -